World Sjögren's Day
23 July 2023
World Sjögren's Day was created to commemorate the birthday of Dr. Henrik Sjögren, the Swedish ophthalmologist who discovered Sjögren's in 1933. World Sjögren's Day is meant to put a face on the millions of people who live with this disease or suffer from symptoms and have yet to be diagnosed. It gives everyone touched by Sjögren's a vehicle to reach out and educate those close to them - family, friends, co-workers, neighbors, etc. - about the disease. It is the ideal opportunity for you to have your voice heard and to spread awareness about this life-altering disease. Sjögren's Foundation
UpToDate
Diagnosis
General
Treatment
Articles
Diagnosis
Research
Risks
Treatment
E-books
E-journals
__________________________________________________________________________________
Articles
Diagnosis
Detection of primary Sjögren’s syndrome in primary care: developing a classification model with the use of routine healthcare data and machine learning
This is the first study to use machine learning to classify patients with Primary Sjögren’s Syndrome (pSS) in primary care using GP electronic health records (EHRs) data. The author’s algorithm has the potential to support the early recognition of pSS in primary care and should be validated and optimized in clinical practice. To further enhance the algorithm in detecting pSS in primary care, we suggest it is improved by working with experienced clinicians. BMC primary care 9 August 2022
Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia
In primary Sjögren’s syndrome (pSS) patients with arthralgia, osteoarthritis (OA) accounted for the majority. pSS patients with advanced age and more pronounced metabolic characteristics, such as elevated blood lipids and uric acid, was a key factor in groups at risk for OA. However, arthritis patients had higher rates of dry mouth and eye, higher disease activity, antibodies positive, and more organs damage. In the future, it may be necessary to be more cautious in the diagnosis of joint manifestations in pSS patients in order to make the appropriate treatments. Journal of orthopaedic surgery and research 16 January 2023
Clinical and laboratory evaluation of sicca complaints: distinctive aspects of primary, secondary and non-Sjogren syndrome
The diagnosis of -Sjogren syndrome (SS) remains a challenge behind dryness. Up to 31% of the suspected cases had other conditions associated to the symptoms. Histopathological analysis of labial salivary gland (LSG) and SSa determined the diagnostic. Aging in pSS and overlap disease in sSS were responsible for distinct phenotypes and characteristic sub-groups in SS.
Prevalence of Sjögren's syndrome according to 2016 ACR-EULAR classification criteria in patients with systemic lupus erythematosus
The prevalence of Sjögren’s Syndrome (SS) in Systemic Lupus Erythematosus (SLE) was 23% (AECG 2002) and 35% (ACR-EULAR 2016). The presence of glandular dysfunction, focal lymphocytic sialadenitis, and anti/Ro were predictors of SS in SLE. The greatest advantage of the new ACR-EULAR 2016 criteria is to enable an early diagnosis and identify the overlapping of these two diseases. ACR-EULAR 2016 criteria is not yet validated for secondary SS and this study is a pioneer in investigating prevalence based on the new criteria. Advances in Rheumatology 14 March 2023
Pediatric rheumatologists’ perspectives on diagnosis, treatment, and outcomes of Sjögren disease in children and adolescents
Pediatric rheumatologists diagnose and treat pedSD; however, most only see a few patients per year and rely on clinical judgment and laboratory testing for diagnosis. Treatment frequently includes systemic immunomodulators and malignancies are reported. More studies are needed to better understand natural history, risk factors, and the impact of interventions on outcomes. Pediatric rheumatology 5 September 2022
Salivary gland ultrasonography in primary Sjögren’s syndrome from diagnosis to clinical stratification: a multicentre study
Salivary gland ultrasonography (SGUS) with the Outcome Measures in Rheumatology Clinical Trials (OMERACT) scoring system yields high sensitivity and specificity, demonstrating high diagnostic feasibility for pSS. The SGUS may have implications for deciding disease severity and treatment efficacy. Arthritis research & therapy 20 December 2021
__________________________________________________________________________________
Research
Analysis of the first tear film break-up point in Sjögren’s syndrome and non-Sjögren’s syndrome dry eye patients
The location of the first tear film break-up point (FTBUP) in Sjögren’s Syndrome dry eye (SSDE) patients had specific characteristics. However, the diagnostic potential of FTBUP in early recognition of SSDE needs further validation. BMC Ophthalmology 3 January 2022
Acute visual loss as the first ocular symptom in a Sjögren’s syndrome patient with bilateral common carotid artery occlusion: a case report
Bilateral common carotid artery occlusion (BCCAO) may be present in patients with Sjögren’s syndrome. Large vessel abnormalities should be considered when acute visual loss is found in a patient with Sjögren’s syndrome. BMC Ophthalmology 27 November 2021
Pain and fatigue are predictors of quality of life in primary Sjögren’s syndrome
The main predictors of poor QoL in patients with pSS were pain and fatigue, and these symptoms had an impact regardless of disease activity, age, schooling, marital status, work disability and fibromyalgia. Advances in Rheumatology 29 May 2021
Unstimulated whole salivary flow in Sjögren’s Syndrome: systematic literature review and meta-analysis
For the first time, the unstimulated whole salivary flow rate is found to be lower in patients with Sjögren’s syndrome compared to controls (healthy and non-SS sicca) through a meta-analysis. Advances in Rheumatology 3 February 2021
Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report
Here, the authors report the case of an Sjogren’s syndrome-Pulmonary arterial hypertension (SS-PAH) patient with Pulmonary veno-occlusive disease (PVOD) who carried a novel biallelic EIF2AK4 mutation, and PAH-targeted therapies were well tolerated by the patient. BMC Pulmonary Medicine 18 January 2023
Primary Sjögren syndrome and development of another autoimmune rheumatic disease during the follow-up
Of all the patients analyzed, 4.4% presented another autoimmune rheumatic disease (ARD) during their follow-up. It is important to be aware of this, to make an early and proper diagnosis and treatment of our patients. Advances in rheumatology 7 June 2022
Olfactory impairment in patients with primary Sjogren’s syndrome and its correlation with organ involvement and immunological abnormalities
These findings indicate that olfactory functions are impaired in pSS patients. There was a close correlation between olfactory dysfunction and disease severity and immunological abnormalities. Immune and systemic inflammation dysregulation might play a role in the mechanism of this defect. Arthritis research & therapy 29 September 2021
Abdominal symptoms during Sjogren’s syndrome: a pilot study
The majority of patients with pSS suffered abdominal symptoms. There is currently no therapeutic recommendation because of the lack of information on the underlying pathophysiological mechanisms. Advances in rheumatology 19 January 2021
__________________________________________________________________________________
Risks
Increased risk of developing Systemic Lupus Erythematosus and Rheumatoid Arthritis in patients with Primary Sjögren’s Syndrome—A secondary cohort analysis of nationwide, population-based claims data
Patients with primary Sjögren’s syndrome (pSS) exhibited an elevated risk of developing systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Rheumatologists should carefully monitor patients with pSS for potential SLE and RA development. Journal of clinical medicine 20 June 2023
Could Primary Hyperparathyroidism be a risk factor for Sjogren’s Syndrome?
Patients with Sjögren's syndrome (SS) have been reported to develop primary hyperparathyroidism (PHPT), and there has been a reported case of primary SS with secondary hyperparathyroidism. However, it is unclear whether PHPT is a risk factor for SS. In this study, the authors report a case of PHPT with SS indicating that PHPT may have a causative role in SS. Journal of case reports 13 June 2023
__________________________________________________________________________________
Treatment
Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: evidence- and practice-based guidance
Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjögren’s syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and refractory/intolerance to conventional immunosuppressants demand other options, namely biological drugs, and small molecules. The authors aimed to define evidence and practice-based guidance for the off-label use of biologics in SLE, APS, and SS. Frontiers in immunology 17 April 2023
Bioengineering in salivary gland regeneration
Salivary gland (SG) dysfunction impairs the life quality of many patients, such as patients with radiation therapy for head and neck cancer and patients with Sjögren’s syndrome. Multiple SG engineering strategies have been considered for SG regeneration, repair, or whole organ replacement. This review summarizes the essential bioengineering features to be considered to fabricate an engineered functional SG model using various cell types, biomaterials, active agents, and matrix fabrication methods. Furthermore, recent innovative and promising approaches to engineering SG models are described. Finally, this review discusses the different challenges and future perspectives in SG bioengineering. Journal of biomedical science 6 June 2023
Long-term effectiveness of a novel intra-oral electro-stimulator for the treatment of dry mouth in patients with Sjogren's syndrome: A randomised sham-controlled feasibility study (LEONIDAS-1)
LEONIDAS-1 results support progression to a phase III definitive randomised controlled trial of salivary electrostimulation in individuals with Sjogren's syndrome. Xerostomia inventory could be considered the primary patient-centred outcome measure and the corresponding observed treatment effect could inform the sample size of a future trial. Journal of oral pathology & medicine 23 May 2023
Effect of autologous plasma used as eye drops in patients with dry eyes in Sjogren’s syndrome: A single-arm trial
This study showed the beneficial effects of autologous plasma eye drops on symptom relief and objective improvement at the end of 3 months. Hence, autologous plasma eye drops can be considered a therapeutic option in patients with SS dry eye disorder. Asian journal of transfusion science 11 May 2023
The diagnosis, treatment, and clinical sequelae of Sjogren’s Syndrome in a pediatric patient: A case report
Sjogren's Syndrome is a chronic multisystem autoimmune condition where lymphocytes attack exocrine glands. Although this condition occurs in pediatric populations, it is often a missed diagnosis or diagnosis made after significant disease progression, frequently leading to extensive investment of time and resources. This case study follows a six-year-old African American female who, after an extensive medical course, was ultimately diagnosed with Sjogren's Syndrome. This case study intends to increase awareness of the potential abnormal presentations of this connective tissue disease in special populations, specifically school-aged pediatric patients. Even with the rarity of this condition in the pediatric population, physicians should keep Sjogren's Syndrome on their differential diagnosis when a patient presents with atypical or non-specific autoimmune-like symptoms. The presentation of children can be more severe than anticipated in an adult. A rapid, multi-disciplinary approach must be implemented to improve the prognosis of pediatric patients with Sjogren's Syndrome. Cureus 28 April 2023
The comparison between the composition of 100% Autologous Serum and 100% Platelet-Rich Plasma eye drops and their impact on the treatment effectiveness of dry eye disease in Primary Sjogren Syndrome
The aim of the study was to compare the difference in composition between 100% autologous serum (AS) and 100% platelet-rich plasma (PRP) eye drops and assess their impact on the clinical outcomes after the treatment of severe dry eye (DE) in primary Sjogren Syndrome patients (pSS). Journal of clinical medicine 25 April 2023
Sjogren's Syndrome: Multidisciplinary approach to diagnosis and management
This article reviews current understanding of the clinical manifestations, diagnosis and treatment of Sjögren's syndrome and its attendant ocular manifestation. Global journal of health sciences 11 February 2023
Outline of salivary gland pathogenesis of Sjögren’s Syndrome and current therapeutic approaches
In this review, the authors provide an overview of the pathogenesis of salivary gland lesions and recent trends in therapeutic approaches for SS. International journal of molecular sciences 6 July 2023
__________________________________________________________________________________
This is just a sample of the e-books the library subscribes to – you will need your library login
__________________________________________________________________________________
This is just a sample of the journals the library subscribes to – you will need your library login
__________________________________________________________________________________
